Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Cancer Discov. 2020 Dec 4;11(3):626–637. doi: 10.1158/2159-8290.CD-20-1579

Figure 4.

Figure 4.

Survival of Black and White AML patients aged ≤60 years who were treated on Alliance protocols and classified into the 2017 European LeukemiaNet (ELN) favorable genetic-risk group. A, disease-free and B, overall survival of NPM1-mutated patients. C, disease-free and D, overall survival of non-NPM1-mutated patients [i.e., patients with biallelic CEBPA mutations or those harboring inv(16)(p13.1q22) or t(8;21)(q22;q22)].